Based on the successful launch of several cancer diagnostic image analysis tool s Visiopharm has initiated an Advisory Board focusing on providing strategic advice to the management with regards to this particular area.
We are very proud to have this particular expert panel to support our efforts in engaging with the medical and scientific community to develop products that are aimed at cancer diagnostic market needs.
Prof. Dr. Manuel Salto-Tellez
Professor Manuel Salto-Tellez (MD-LMS, FRCPath, FRCPI) is the Chair of Molecular Pathology at Queen’s University Belfast, Clinical Consultant Pathologist at the Belfast Health and Social Care Trust and Deputy Director of the Centre for Cancer Research and Cell Biology. By February 2016, Prof. Salto-Tellez was author or co-author of more than 210 internationally peer-reviewed articles in translational science, molecular pathology and diagnostics, including work published in NEJM, Nature Medicine, Gastroenterology, FASEB, EMBO, Cancer Research and Clinical Cancer Research, among others. He has published a similar number of abstracts in international conferences, and is editor or contributor to some of the key textbooks of pathology and oncology. Prof Salto-Tellez serves in a little more than 10 different committees amongst them UKNEQAS Committee for DNA Quality and as Chair of the Working Group on Pathology, Imaging and Diagnostics of Bowel Cancer UK. He is also in the editorial board in more than 4 esteemed journals.”
Prof. Dr. Mogens Vyberg
Professor Mogens Vyberg graduated with MD in medicine 1973 and was board-certified as specialist in pathology 1984. Since 1988, he has been senior consultant at the Institute of Pathology, Aalborg University Hospital, and was appointed as professor of clinical pathology at Aalborg University in 2012. Prof. Vyberg’s main clinical expertise and research fields are gastrointestinal, liver and brain pathology, immunohistochemistry and image analysis. He is author and co-author of about 130 peer reviewed scientific papers and conference abstracts, and several book chapters in these fields. He is head of the Laboratory for immunohistochemistry/R&D, which carries out quality control and protocol optimization for the world’s leading diagnostics companies. Prof. Vyberg is also co-founder and director of the international organization Nordic Immunohistochemical Quality Control (NordiQC, www.nordiqc.org), which was established in 2003 at the Institute of Pathology, Aalborg University Hospital, and currently serves more than 700 pathology laboratories from 85 countries. Prof. Vyberg is board member of the International Quality Network Pathology and the International Society for Immunohistochemistry and Molecular Morphology.
Keith Miller, FIBMS, Scheme Director, UK NEQAS
Keith Miller, a Fellow of the Institute of Biomedical Sciences, has been employed at University College London as a medical scientist in pathology over several decades. He has been privileged to work with some outstanding academics, including Professor Peter Isaacson, who is associated with the discovery of Gastric MALT Lymphoma. Keith Miller's IHC laboratory played a pivotal role in providing the necessary evidence for this new entity. Keith Miller is a founding member and current Director of the UK National External Quality Assessment Scheme for Immunocytochemistry and In-situ Hybridisation. He has also developed the Advanced Diagnostics IHC & ISH clinical laboratory at UCL and this is now one of the largest testing centers of its kind in Europe today. Keith Miller has considerable experience with EQA in immunohistochemistry and related technology and has published extensively over the years. The pitfalls of setting up laboratory developed tests as companion diagnostics are well known to him. Keith Miller is continuously raising concerns about this issue as more and more targeted therapies are being released that require an IHC test as a companion diagnostic.
Prof. Dr. Ben Vainer
Professor Ben Vainer is clinical professor of pathology and consultant at Dept. of Pathology, Rigshospitalet, University of Copenhagen, with digitalization of the development, scientific testing and implementation of digital methods in diagnostic pathology and in research and education as his primary administrative and research obligations. Study areas in addition included neoplastic and non-neoplastic liver diseases, prostate cancer and colorectal cancer. As Professor at the University of Copenhagen, Ben Vainer has developed and implemented digital methods in the teaching curriculum in the courses of pathology for medical students and students in odontology and human biomedicine, including virtual microscopy, lecture streaming, blogs, and remote education. Please visit www.virmik.sund.dk. Professor Ben Vainer is chief editor at APMIS, serves in a number of different scientific committees and in the Board of Studies of Medicine, University of Copenhagen, and as external reviewer at several scientific journals. Presently, supervisor of 9 PhD students and 6 pre-graduate students. Prof. Ben Vainer is author or co-author of more than 115 publications, H-index: 26; citations: 2396.
Assoc. Prof. Dr. Anne-Vibeke Lænkholm
Dr. Anne-Vibeke Lænkholm is an associate professor at the Department of Pathology, Zealand University Hospital, Denmark. Her main interest is diagnostic breast pathology and translational breast cancer research.
In addition, she serves in a number of different committees amongst them as board member of The Danish Breast Cancer Cooperative Group (DBCG) and as member of the NordiQC HER-2 ISH Assessor Group and the EWGBSP. Associate prof. Anne-Vibeke Lænkholm is author or co-author of more than 45 peer reviewed articles.
Assoc. Prof. Dr. Johan Hartman
Johan Hartman is an associate professor of pathology at Karolinska University Laboratory, Stockholm, Sweden. His clinical interest is breast pathology. He is a PI at dept. of Oncology and Pathology, Karolinska Institutet and his research team is involved in both clinical and translational projects.
His main research focus is cancer stem cells,cancer genomics/transcriptomics and image analysis for therapy prediction. Johan is heavily involved in the implementation of personalized cancer medicine at Karolinska. Associate prof. Johan Hartman is author or co-author of more than 35 peer reviewed articles, many in high-impact journals and with totally more than 2500 citations.